Results 81 to 90 of about 64,107 (288)

The First Nationwide Surveillance of Severe Fever with Thrombocytopenia Syndrome in Ruminants and Wildlife in Taiwan

open access: yesViruses, 2023
Since the first discovery of severe fever with thrombocytopenia syndrome virus (SFTSV) in China in 2009, SFTSV has rapidly spread through other Asian countries, including Japan, Korea, Vietnam and Pakistan, in chronological order.
Chih-Ying Kuan   +23 more
doaj   +1 more source

The cap-snatching SFTSV endonuclease domain is an antiviral target [PDF]

open access: yes, 2020
Severe fever with thrombocytopenia syndrome virus (SFTSV) is a tick-borne virus with 12%-30% case mortality rates and is related to the Heartland virus (HRTV) identified in the United States.
Amarasinghe, Gaya K   +11 more
core   +1 more source

Serum proteomics of severe fever with thrombocytopenia syndrome patients

open access: yesClinical Proteomics, 2022
AbstractBackgroundDabie bandavirus, also termed as severe fever with thrombocytopenia syndrome virus (SFTSV), was first isolated in China in 2010. At this time, the virus was found to have spread to South Korea, Japan, and other countries. A high case fatality rate is reported for SFTS, ranging from 12–50% within various sources.
Lee, Sang-Yeop   +8 more
openaire   +2 more sources

Effectiveness and safety of tocilizumab combined with different high‐dose methylprednisolone regimens for acute necrotizing encephalopathy in children

open access: yesPediatric Investigation, EarlyView.
Tocilizumab combined with high‐dose methylprednisolone improved outcomes in children with acute necrotizing encephalopathy. A dose of 30 mg/(kg·day) may be more effective than 20 mg/(kg·day). ABSTRACT Importance Acute necrotizing encephalopathy (ANE) is a rare but life‐threatening pediatric neurological disorder characterized by rapid progression and ...
Fei Li   +4 more
wiley   +1 more source

Transmission of Severe Fever with Thrombocytopenia Syndrome Virus by Haemaphysalis longicornis Ticks, China

open access: yesEmerging Infectious Diseases, 2018
We demonstrate maintenance and transmission of severe fever with thrombocytopenia syndrome virus by Haemaphysalis longicornis ticks in the larva, nymph, and adult stages with dissemination in salivary gland, midgut, and ovarian tissues.
Lu Zhuang   +11 more
doaj   +1 more source

Feminization and severe pancytopenia caused by testicular neoplasia in a cryptorchid dog [PDF]

open access: yes, 2016
In this case report, a paraneoplastic syndrome caused by testicular neoplasia in a ten-year-old cryptorchid dog is described. Feminization and pancytopenia were observed, resulting from the testicular neoplastic production of estrogens.
Hebbelinck, Lien   +3 more
core  

Severe fever with thrombocytopenia syndrome in children: a case report [PDF]

open access: yes, 2014
BACKGROUND: Severe fever with thrombocytopenia syndrome (SFTS) is an emerging infectious disease caused by a novel bunyavirus (SFTSV) in China. Humans of all ages living in endemic areas have high risk of acquiring SFTS.
Hong-Yu Wang   +6 more
core   +2 more sources

Early prognosis biomarkers of severe fever with thrombocytopenia syndrome

open access: yesiLABMED
Severe fever with thrombocytopenia syndrome (SFTS) is an emerging infectious disease that results from SFTS bunyavirus (SFTSV) infection. Infection with SFTSV can activate the immune system, producing a series of inflammatory factors.
Mingrong Ou   +6 more
doaj   +1 more source

Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus [PDF]

open access: yes, 2016
Although there are high survival rates for children with acute lymphoblastic leukaemia, their outcome is often counterbalanced by the burden of toxic effects.
Attarbaschi, Andishe   +20 more
core   +2 more sources

Long‐Term Efficacy and Safety of Ligelizumab as Re‐Treatment in Patients With Chronic Spontaneous Urticaria

open access: yesAllergy, EarlyView.
Ligelizumab re‐treatment in CSU patients showed sustained efficacy and tolerability. Over 50% achieved symptom control (UAS7 ≤ 6) by Week 12; benefits maintained through Week 52. No new safety signals observed; aligns with prior PEARL trial outcomes. CSU, chronic spontaneous urticaria; mg, milligram; q4w, every 4 weeks; UAS, urticaria activity score ...
Ana M. Gimenez‐Arnau   +22 more
wiley   +1 more source

Home - About - Disclaimer - Privacy